Sign in
CompletedPhase 1

Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

Key facts

Who runs it
Grace Lim, MD, MS
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
12 people enrolled
Started
25 Sept 2023
Ended
19 Sept 2024
Type of study
Interventional, 4 groups
Treatments tested
  • Ketamine (Ketalar) Dose Level 1
  • Ketamine (Ketalar) Dose Level 2
  • Ketamine (Ketalar) Dose Level 3
  • Ketamine (Ketalar) Dose Level 4
Record updated
12 September 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Adults 18 years and older
  • Cesarean Delivery
  • American Society of Anesthesiologists Physical Status of 2 or 3
  • Neuraxial anesthesia with neuraxial morphine
  • Term delivery ≥37 weeks gestation
  • Either planning not to breastfeed, OR receiving ketamine as part of routine clinical care

Who cannot take part

  • Allergy to study medications
  • Hypertensive disorder of pregnancy
  • Medical History exclusions: ketamine or PCP (phencyclidine) abuse, schizophrenia or psychosis, liver or renal insufficiency, uncontrolled hypertension, chest pain, arrhythmia, head trauma, or intracranial hypertension, uncontrolled thyroid disease, or other contraindications to ketamine
  • General anesthesia
  • ASA PS 4 or higher
  • Contraindications to neuraxial anesthesia
  • Preterm delivery (<37 weeks gestation)
  • Anticipated fetal-neonatal complex care plan
  • Participating in another pain intervention trial
  • Pre-eclampsia with severe features
  • Hemodynamic instability

Where in United States

  • Magee-Womens Hospital of UPMCPittsburgh, United States

About the trial

What the trial wants to find out

The purpose of this study is to identify a tolerable dose for postpartum ketamine infusion using a maximum tolerated dose (MTD) 3+3 design. A loading dose over 1 hour will be the MTD variable to be tested, as our data suggest that ketamine side effects occur with the loading dose. The investigators hypothesize that subanesthetic ketamine dose will be well tolerated and any noted side effects will be rated acceptable by postpartum women following cesarean delivery.

The 4 groups in the trial

  • Ketamine (Ketalar) Dose Level 1Treatment being tested

    Ketamine (Ketalar) Dose Level 1: Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

  • Ketamine (Ketalar) Dose Level 2Treatment being tested

    Ketamine (Ketalar) Dose Level 2: Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

  • Ketamine (Ketalar) Dose Level 3Treatment being tested

    Ketamine (Ketalar) Dose Level 3: Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

  • Ketamine (Ketalar) Dose Level 4Treatment being tested

    Ketamine (Ketalar) Dose Level 4: Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE1)
Record updated
12 September 2025